BVES-HA IP-mass from AAV9-BVES-HA injected mouse skeletal muscle
Ontology highlight
ABSTRACT:
INSTRUMENT(S): 6410 Triple Quadrupole LC/MS
ORGANISM(S): Mus Musculus (mouse)
SUBMITTER: 
Haiwen Li
LAB HEAD: Renzhi Han
PROVIDER: PXD036346 | Pride | 2023-02-27
REPOSITORIES: Pride
Similar Datasets
Project description:Forkhead BoxO (FoxO) transcription factors expressed in adult skeletal muscle promote muscle atrophy during various catabolic conditions. We have identified the genome wide target genes and biological networks regulated by FoxO in skeletal muscle during Colon-26 (C-26) cancer cachexia. In this dataset, we include the expression data obtained from the tibialis anterior muscles of control and severely cachectic Colon-26 mice in which FoxO-dependent transcription was either intact (AAV9-EV) or inhibited (AAV9-d.n.FoxO). These data were used to obtain 543 FoxO target genes during cancer. These target genes were identified as those genes whose expression was both differentially regulated in skeletal muscle in response to cancer (control AAV9-EV vs. C26 AAV9-EV), and differentially regulated in the presence of d.n.FoxO (C26 AAV9-EV vs. C26 AAV9-d.n.FoxO).
2014-12-31 | GSE56555 | GEO
Project description:Acinetobacter sp. HA strain:HA Genome sequencing and assembly
| PRJNA158435 | ENA
Project description:Labyrinthula sp. Ha isolate:Ha Genome sequencing and assembly
| PRJNA607370 | ENA
Project description:We used miRNA microarrays to detail the miRNA content in A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells
2024-04-18 | GSE255941 | GEO
Project description:TFE3 is a bHLH-ZIP transcription factor, which nuclear localization is regulated by a tumor suppressor FLCN. In order to analyze TFE3 occupancy in whole genome, we have generated and utilized a HK-2 HA-TFE3-inducible cell line which express HA-tagged TFE3 in a doxycycline-dependent manner. HA-TFE3 bound regions were determined by ChIPSeq.
2020-08-07 | GSE135490 | GEO
Project description:As an approach to improve efficacy and provide clinical benefit to cancer patients undergoing chemotherapeutic treatment regimens, Alchemia Oncology has developed a novel means for delivering anti-cancer agents to tumours. The drug delivery platform is based on the use of hyaluronic acid (HA), a novel excipient, in which, formulation with HA results in optimisation of cytotoxic drug uptake and retention within solid tumours. In the specific example of HA-Irinotecan, this new formulation of irinotecan has demonstrated enhanced efficacy in both nonclinical and early clinical studies.
The current study is an investigation into the use of HA-Irinotecan in a Phase II single arm trial of FOLF(HA)iri plus cetuximab in irinotecan-naïve second line patients with KRAS wild type metastatic colorectal cancer. The study objectives are to confirm the safety and efficacy of FOLF(HA)iri plus cetuximab as second-line therapy in irinotecan-naïve metastatic colorectal cancer patients.
It is expected that the study recruit approximately 40-50 patients in 1 year with subsequent treatment and follow up; thus the trial will run for approximately 2-3 years.
| 2172573 | ecrin-mdr-crc
Project description:Texel and Ujumqin sheep show obvious differences in muscle and fat growth, so they are ideal models not only to understand the molecular mechanism in prenatal skeletal muscle development, but to identify the potential target genes of myostatin. To elucidate the phenotypic variation between the two sheep breeds and the dynamic characteristics of gene expression in skeletal muscle during the development, we examined the development of skeletal muscle in transcriptome-wide level at 70, 85,100,120 , 135 days post coitus (dpc),birth, 1 month and 2 month. Using the specialized and standardized sheep transcriptome-wide oligo DNA microarray (Agilent), we analyzed the transcriptomic profiles of longissmuss dorsi muscle from fetuses of Texel and Ujumqin sheep. We characterized dynamic transcriptome-wide profiles that accompany the prenatal skeletal muscle and fat development in Texel and Ujumqin sheep respectively, and compared the difference in profiles of gene expression between the two sheep breeds at the same developmental stage.Some potential myostatin target genes and other genes controlling the growth of skeletal muscle and adipose were identified for further examinations. Our findings not only contribute to understand the molecular mechanism of prenatal skeletal muscle development in large precocial species, but also provide some clues for human myopathy and obesity at prenatal stages. Moreover, we also can identify putative candidate genes for meat quality traits in farm animals. Longissimus dorsi muscles were sampled from five prenatal development stages (70, 85, 100, 120 and 135 day of gestation) in Texel and eight development stages (at 70, 85, 100, 120, 135 days post coitus (dpc), birth, 1 month and 2 month) in Ujumqin sheep. There were at least three replicates at each development time in each breed. Two gene expression experiments were conducted with a total of 40 hybridizations.
2010-12-20 | E-GEOD-23563 | biostudies-arrayexpress
Project description:Trial design:
* Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen.
* Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
* Randomized 1:1, double-blinded, multi-centre, multi-national (Australia, Bulgaria, Poland, Serbia, Russia, Ukraine and the United Kingdom).
* Dosing regimen:
* Irinotecan (180 mg/m2) or HA-Irinotecan (180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan and HA-Irinotecan dose in must be reduced to 150 mg/m2).
* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
* 5-fluorouracil (5-FU), 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
* Repeat every 2 weeks for 8 months.
* Patient accrual over approximately 12-14 months.
* Monitoring to 18 months post-randomization.
* 390 patients.
* Progression Free Survival (PFS) primary endpoint.
* Safety analysis on the initial 20 patients.
| 2101890 | ecrin-mdr-crc
Project description:Purpose: RNA-seq analysis of the pbl19/pPBL19:PBL19C3A-GFP-HA, sid2pbl19/pPBL19:PBL19C3A-GFP-HA and eds1pbl19/pPBL19:PBL19C3A-GFP-HA plants and identified a large number of differentially expressed genes in these plants relative to wild-type plants. Methods: For RNA-seq analyses, a total amount of 1 mg RNA per sample was used for RNA-seq library construction. Results: RNA-seq analysis of wild type(WT), pbl19/pPBL19:PBL19C3A-GFP-HA, sid2pbl19/pPBL19:PBL19C3A-GFP-HA and eds1pbl19/pPBL19:PBL19C3A-GFP-HA at 28 DAG.Numbers of differentially expressed genes in pbl19/pPBL19::PBL19C3A-GFP-HA plants compared to WT.1981 differentially expressed genes were constantly up-regulated in pbl19/pPBL19::PBL19C3A-GFP-HA plants compared to WT Conclusions: Receptor-like cytoplasmic kinase PBL19 exhibited the highest transcriptional upregulation among the forty-six genes of the RLCK VII subfamily in pbl19/pPBL19C3A-GFP-HA and sid2 pbl19/pPBL19C3A-GFP-HA transgenic plants.eds1 pbl19/pPBL19:PBL19C3A-GFP-HA plants were fully restored to a wild-type(WT) appearance
2021-11-16 | GSE188663 | GEO
Project description:Naked mole-rat skin fibroblasts (NSF) produces vHMM-HA. Although NSF-HA has been shown to suppress NSF transformation, it is still unclear if exceptional polymer length of vHMM-HA is important for its functions. Here, we compared the effect of intact control NSF-HA (cNSF-HA) and partially fragmented NSF-HA (fNSF-HA) on the transcriptome of IMR90 cells. Related RNA-Seq datasets are deposited in ArrayExpress (E-MTAB-8943).
2019-01-01 | GSE116759 | GEO